A Phase III Study of Jaktinib in Adults With Moderate and Severe Atopic Dermatitis
Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
A multicenter, randomized, double-blind, placebo-controlled phase III clinical study of
jaktinib hydrochloride tablets in the treatment of adult patients with moderate and severe
atopic dermatitis